Integrating Emerging Evidence into the Management of Patients with Chronic Lymphocytic Leukemia

The goal of this activity is to improve the ability to optimize therapy and incorporate clinical advances into the management of patients with chronic lymphocytic leukemia.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other health care professionals who provide care for patients with hematologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal treatment for patients with newly diagnosed chronic lymphocytic leukemia based on patient-specific and disease-specific factors
  • Choose optimal treatment for relapsed/refractory chronic lymphocytic leukemia in special patient populations
  • Explain how promising investigational agents may fit into the current treatment paradigm for chronic lymphocytic leukemia
Additional information
Supporters: 

This activity is supported by educational grants from AbbVie Inc.; Genentech; and Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc.

Course summary
Available credit: 
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
12/15/2015
Course expires: 
12/15/2016
Cost:
$0.00

William G. Wierda, MD, PhD
The University of Texas MD Anderson Cancer Center

Andrew D. Zelenetz, MD, PhD
Memorial Sloan Kettering Cancer Center

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below have disclosed the following relevant financial relationships:

Jacqueline Barrientos, MD, has disclosed that she has served on advisory boards for AbbVie, Gilead Sciences, and Pharmacyclics.

Jennifer R. Brown, MD, PhD, has disclosed that she has received consulting fees from Celgene, Genentech/Roche, Gilead Sciences, Infinity, Janssen, Pharmacyclics, ProNai, and Sun BioPharma.
Steven E. Coutre, MD, has disclosed that he has received consulting fees from Gilead Sciences and Janssen and funds for research support from AbbVie, Celgene, Gilead Sciences, Janssen, and Pharmacyclics.

Thomas J. Kipps, MD, PhD, has disclosed that he has served on a speakers bureau for Gilead Sciences; has received honoraria from AbbVie, Celgene, Gilead Sciences, and Pharmacyclics; has received consulting fees from AbbVie, Celgene,Roche, and Pharmacyclics; and has received funds for research support from AbbVie, Celgene, and Roche.

William G. Wierda, MD, PhD, has disclosed the following: AbbVie: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor; Ascerta: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor; Celgene Corporation: Consulting Fees, Honoraria; Scientific Advisor; Emergent BioSolutions Inc.: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor; Genentech, Inc.: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor; Genzyme Corporation: Consulting Fees, Honoraria; Scientific Advisor; Gilead Sciences: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor; GlaxoSmithKline: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor; Juno Therapeutics: Grant/Research Support; Karyopharm: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor; Kite Pharma: Grant/Research Support; Merck & Co., Inc.: Consulting Fees, Honoraria; Scientific Advisor; Novartis Pharmaceuticals Corporation: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor; Pharmacyclics: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor; Roche Laboratories, Inc.: Consulting Fees, Honoraria; Grant/Research Support; Scientific Advisor; sanofi-aventis U.S.: Consulting Fees, Honoraria; Scientific Advisor.

Andrew D. Zelenetz, MD, PhD, has disclosed the following: Amgen Inc.: Consulting Fees, Honoraria; Boehringer Ingelheim GmbH: Scientific Advisor; Bristol-Myers Squibb Company: Grant/Research Support; Celgene Corporation: Consulting Fees, Honoraria; Gilead Sciences, Inc.: Consulting Fees, Honoraria; Grant/Research Support; GlaxoSmithKline: Consulting Fees, Honoraria; Grant/Research Support; Hospira: Consulting Fees, Honoraria; Medscape: Consulting Fees, Honoraria; Roche Laboratories, Inc.: Consulting Fees, Honoraria; Grant/Research Support.

The activity planning staff listed below has no relevant financial relationships to disclose:
CCO: Kevin Obholz, PhD, and Gordon Kelley have no relevant financial relationships to disclose.
NCCN: Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Joan S. McClure, MS; Diane McPherson; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; and Jennifer McCann Weckesser

The NCCN clinical information team listed below, who has reviewed content, has no relevant financial relationships to disclose: Hema Sundar, PhD

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this CE activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Nurse Planner: Kristina M. Gregory, RN, MSN, OCN, is the nurse planner for all NCCN educational activities.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. NCCN and Clinical Care Options, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of NCCN and Clinical Care Options, LLC. Please refer to the official prescribing information for each product for discussion of approved indication, contraindications, and warnings.

Physicians
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of NCCN and Clinical Care Options, LLC. The NCCN is accredited by the ACCME to provide continuing medical education for physicians.

National Comprehensive Cancer Network designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release date: December 15, 2015
Expiration date: December 15, 2016

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Release date: December 15, 2015
Expiration date: December 15, 2016

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge 

National Comprehensive Cancer Network designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-9999-15-127-H01-P

Release date: December 15, 2015
Expiration date: December 15, 2016

Available Credit

  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Accreditation Period

Course opens: 
12/15/2015
Course expires: 
12/15/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader or other PDF reader software for certificate viewing/printing